iconEarnings Announcement Before Market Open

Inhibikase Therapeutics Inc IKT:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 7:39 PM EDT
2.00quote price arrow up+0.01 (+0.50%)
Volume
2,948
Close
1.99quote price arrow up+0.45 (+29.22%)
Volume
482,209
52 week range
0.79 - 4.35
Loading...
  • Open1.58
  • Day High2.22
  • Day Low1.55
  • Prev Close1.54
  • 52 Week High4.35
  • 52 Week High Date06/02/23
  • 52 Week Low0.79
  • 52 Week Low Date10/10/23

Key Stats

  • Market Cap12.889M
  • Shares Out6.48M
  • 10 Day Average Volume0.05M
  • Dividend-
  • Dividend Yield-
  • Beta1.33
  • YTD % Change56.69

KEY STATS

  • Open1.58
  • Day High2.22
  • Day Low1.55
  • Prev Close1.54
  • 52 Week High4.35
  • 52 Week High Date06/02/23
  • 52 Week Low0.79
  • 52 Week Low Date10/10/23
  • Market Cap12.889M
  • Shares Out6.48M
  • 10 Day Average Volume0.05M
  • Dividend-
  • Dividend Yield-
  • Beta1.33
  • YTD % Change56.69

RATIOS/PROFITABILITY

  • EPS (TTM)-3.62
  • P/E (TTM)-0.55
  • Fwd P/E (NTM)-1.04
  • EBITDA (TTM)-19.912M
  • ROE (TTM)-118.88%
  • Revenue (TTM)260,500.014
  • Gross Margin (TTM)-
  • Net Margin (TTM)-7,304.76%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/15/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Inhibikase Therapeutics Inc

 

Profile

MORE
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson...
Milton Werner Ph.D.
President, Chief Executive Officer, Director
Garth Lees-Rolfe
Chief Financial Officer
Address
3350 Riverwood Parkway Se, Suite 1900
Atlanta, GA
30339
United States